Literature DB >> 31064935

Recurrent venous thrombosis during direct oral anticoagulant therapy in a patient with protein S deficiency.

Shusuke Yagi1,2, Kumiko Kagawa3, Eiki Fujimoto4, Masataka Sata1.   

Abstract

Protein S (PS) deficiency is an inherited thrombophilia associated with an increased risk of venous thromboembolism (VTE). In Japan, unfractionated heparin followed by warfarin has been historically applied for the treatment of VTE. Recent evidence showed that direct oral anticoagulants (DOACs) were non-inferior to standard therapy with warfarin, with significantly less bleeding in patients with VTE. However, it is unknown whether DOACs are effective for the treatment of VTE in patients with thrombophilia, including protein S deficiency, due to lack of evidence. Here, we report a case of recurrent venous thrombosis during edoxaban therapy in a patient with protein S deficiency, which was successfully treated using high-dose apixaban therapy. J.Med. Invest. 66 : 182-184, February, 2019.

Entities:  

Keywords:  VTE; apixavan; congenital thrombophilia

Mesh:

Substances:

Year:  2019        PMID: 31064935     DOI: 10.2152/jmi.66.182

Source DB:  PubMed          Journal:  J Med Invest        ISSN: 1343-1420


  3 in total

1.  Successful endovascular therapy for an adolescent patient with cerebral venous sinus thrombosis: A case report.

Authors:  Tao Peng; Zini Zhang; Bifeng Zu; Bitang Dan
Journal:  Medicine (Baltimore)       Date:  2021-09-03       Impact factor: 1.817

Review 2.  Inherited Thrombophilia in the Era of Direct Oral Anticoagulants.

Authors:  Lina Khider; Nicolas Gendron; Laetitia Mauge
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

Review 3.  Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins, and clotting factors for transfusion support in patients with hematologic disease.

Authors:  Prajeeda M Nair; Matthew J Rendo; Kristin M Reddoch-Cardenas; Jason K Burris; Michael A Meledeo; Andrew P Cap
Journal:  Semin Hematol       Date:  2020-07-27       Impact factor: 3.851

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.